Filed by Cigna Corporation
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Cigna Corporation and Express Scripts Holding Company
(Commission File No. 001-08323)
Date: March 8, 2018
On March 8, 2018, Cigna Corporation made available the following talking points.
Employee/Manager Talking Points
|
· |
As you learned in the letter from David, Cigna announced today the acquisition of Express Scripts, a leading pharmacy services company that makes the use of medicine safer and more affordable for over 80 million people, to create a dramatically expanded portfolio of integrated health services for employers, health plans and government agencies.
|
|
· |
We are excited about this compelling combination as it brings together two innovative, complementary and customer-centric health service leaders to chart a healthier, more affordable, and more personalized health care journey for people. Together, we have the unique opportunity to drive toward a better future of health care, positively impacting millions of more lives.
|
|
· |
Our acquisition of Express Scripts builds upon our enterprise strategy to "Go Deeper", "Go Local" and "Go Beyond", further expanding our capabilities across pharmacy and physician engagement, retail and government risk-based programs.
|
|
· |
This transaction was made possible due to your hard work and commitment to serving our customers, clients, and business and physician partners, and the best-in-class results you have achieved. We come into this transaction from a position of strength building upon numerous successes, growing our number of customer relationships to more than 94 million and consistently outperforming our competition with superior results for our customers, clients and shareholders.
|
|
· |
I'm sure you have questions about what this means for you and the company, and we will provide you updates as appropriate. Importantly, there will not be any immediate changes to your day-to-day role as a result of today's announcement. Until the transaction closes, which we expect by the end of 2018, our two companies will remain separate and independent, and we expect you to continue to compete to win in your area as you have always done.
|
|
· |
Both organizations will work to develop a smooth integration plan for the combined company once we have secured necessary regulatory and shareholder approvals for the transaction, and we will keep you updated as we have developments to share.
|
|
· |
Today through transaction closing, unwavering focus on our customers and stability will still be important. We must continue to focus on delivering quality health care services for our clients and customers without disrupting the value we already bring.
|
|
· |
Once the transaction closes, David will continue as President and Chief Executive Officer and Tim Wentworth will assume the role of President, Express Scripts. The leadership team of the combined company will be accountable for delivering on a successful integration and the results of the enterprise after closing.
|
|
· |
Additionally, our employees will remain a key differentiator in the combined company. We are committed to supporting each of you in your career journey and believe that this combination will open up additional opportunities for growth and development and the ability to make a more meaningful impact.
|
|
· |
As always, thank you for your continued hard work and contributions to-date that has made today possible.
|
# # #
FORWARD LOOKING STATEMENTS
Information included or incorporated by reference in this communication, and information which may be contained in other filings with the Securities and Exchange Commission (the "SEC") and press releases or other public statements, contains or may contain forward-looking statements. These forward-looking statements include, among other things, statements of plans, objectives, expectations (financial or otherwise) or intentions.
Forward-looking statements, including as they relate to Express Scripts ("Express Scripts") or Cigna ("Cigna"), the management of either such company or the transaction, involve risks and uncertainties. Actual results may differ significantly from those projected or suggested in any forward-looking statements. Express Scripts and Cigna do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following:
|
· |
the inability of Express Scripts and Cigna to obtain stockholder or regulatory approvals required for the merger or the requirement to accept conditions that could reduce the anticipated benefits of the merger as a condition to obtaining regulatory approvals;
|
|
· |
a longer time than anticipated to consummate the proposed merger;
|
|
· |
problems regarding the successful integration of the businesses of Express Scripts and Cigna;
|
|
· |
unexpected costs regarding the proposed merger;
|
|
· |
diversion of management's attention from ongoing business operations and opportunities;
|
|
· |
potential litigation associated with the proposed merger;
|
|
· |
the ability to retain key personnel;
|
|
· |
the availability of financing;
|
|
· |
effects on the businesses as a result of uncertainty surrounding the proposed merger; and
|
|
· |
the industry may be subject to future risks that are described in SEC reports filed by Express Scripts and Cigna.
|
You should carefully consider these and other relevant factors, including those risk factors in this communication and other risks and uncertainties that affect the businesses of Express Scripts and Cigna described in their respective filings with the SEC, when reviewing any forward-looking statement. These factors are noted for investors as permitted under the Private Securities Litigation Reform Act of 1995. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider either foregoing lists, or the risks identified in SEC filings, to be a complete discussion of all potential risks or uncertainties.
IMPORTANT INFORMATION ABOUT THE TRANSACTION AND WHERE TO FIND IT
This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. In connection with the proposed transaction, the newly formed company which will become the holding company following the transaction ("Holdco") intends to file with the SEC a registration statement on Form S-4 that will include a joint proxy statement of Cigna and Express Scripts that also constitutes a prospectus of Holdco. Cigna and Express Scripts also plan to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. You may obtain a free copy of the joint proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by Holdco, Cigna and Express Scripts with the SEC at the SEC's website at www.sec.gov. Copies of documents filed with the SEC by Cigna will be available free of charge on Cigna's website at www.Cigna.com or by contacting Cigna's Investor Relations Department at (215) 761-4198. Copies of documents filed with the SEC by Express Scripts will be available free of charge on Express Scripts' website at www.express-scripts.com or by contacting Express Scripts' Investor Relations Department at (314) 810-3115.
PARTICIPANTS IN THE SOLICITATION
Cigna (and, in some instances, Holdco) and Express Scripts and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction under the rules of the SEC. Investors may obtain information regarding the names, affiliations and interests of directors and executive officers of Cigna (and, in some instances, Holdco) in Cigna's Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 28, 2018, and its preliminary proxy statement for its 2018 Annual Meeting, which was filed with the SEC on March 2, 2018. Investors may obtain information regarding the names, affiliations and interests of Express Scripts' directors and executive officers in Express Scripts' Annual Report on Form 10-K for the
year ended December 31, 2017, which was filed with the SEC on February 27, 2018, and its proxy statement for its 2017 Annual Meeting, which was filed with the SEC on March 17, 2017. You may obtain free copies of these documents at the SEC's website at www.sec.gov, at Cigna's website at www.Cigna.com or by contacting Cigna's Investor Relations Department at (215) 761-4198. Copies of documents filed with the SEC by Express Scripts will be available free of charge on Express Scripts' website at www.express-scripts.com or by contacting Express Scripts' Investor Relations Department at (314) 810-3115. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction if and when they become available. Investors should read the joint proxy statement/prospectus carefully and in its entirety when it becomes available before making any voting or investment decisions.
NO OFFER OR SOLICITATION
This communication is for informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law.